Objective: ATL1103 is a second-generation antisense oligomer targeting the human growth hormone (GH) receptor. This
phase 2 randomised, open-label, parallel-group study assessed the potential of ATL1103 as a treatment for acromegaly.
Design: Twenty-six patients with active acromegaly (IGF-I >130% upper limit of normal) were randomised to subcutaneous
ATL1103 200mg either once or twice weekly for 13 weeks and monitored for a further 8-week washout period.
Methods: The primary efficacy measures were change in IGF-I at week 14, compared to baseline and between cohorts.
For secondary endpoints (IGFBP3, acid labile subunit (ALS), GH, growth hormone-binding protein (GHBP)), comparison
was between baseline and week 14. Safety was assessed by reported adverse events.
Results and conclusions: Baseline median IGF-I was 447 and 649 ng/mL in the once- and twice-weekly groups
respectively. Compared to baseline, at week 14, twice-weekly ATL1103 resulted in a median fall in IGF-I of 27.8%
(P = 0.0002). Between cohort comparison at week 14 demonstrated the median fall in IGF-I to be 25.8% (P = 0.0012)
greater with twice-weekly dosing. In the twice-weekly cohort, IGF-I was still declining at week 14, and remained
lower at week 21 than at baseline by a median of 18.7% (P = 0.0005). Compared to baseline, by week 14, IGFBP3 and
ALS had declined by a median of 8.9% (P = 0.027) and 16.7% (P = 0.017) with twice-weekly ATL1103; GH had increased
by a median of 46% at week 14 (P = 0.001). IGFBP3, ALS and GH did not change with weekly ATL1103. GHBP fell by a
median of 23.6% and 48.8% in the once- and twice-weekly cohorts (P = 0.027 and P = 0.005) respectively. ATL1103 was
well tolerated, although 84.6% of patients experienced mild-to-moderate injection-site reactions. This study provides
proof of concept that ATL1103 is able to significantly lower IGF-I in patients with acromegaly.
CORE (COnnecting REpositories)
CORE (COnnecting REpositories)